Bristol Myers Squibb (BMY) Stock Moves -0.67%: What You Should KnowZacks Investment Research • 07/11/21
Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone paymentsMarket Watch • 07/06/21
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior ChemotherapyBusiness Wire • 06/29/21
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following ChemoradiotherapyBusiness Wire • 06/25/21
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple MyelomaBusiness Wire • 06/25/21
Bristol Myers Onureg Scores European Approval As Maintenance Therapy For Acute Myeloid LeukemiaBenzinga • 06/18/21
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid LeukemiaBusiness Wire • 06/18/21
Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For RightsBenzinga • 06/18/21
Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug ConjugateBusiness Wire • 06/17/21